Results 111 to 120 of about 26,125 (257)

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

British Journal of Haematology, EarlyView.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall, James Croft, Katrina Walker, Kevin Boyd, Sadie Roberts, Amy Holroyd, Mamta Garg, Elsa Ferris, Gordon Cook, William E. Pierceall, Anjan Thakurta, Anita Gandhi, Charlotte Pawlyn, Sarah R. Brown, Martin Kaiser   +14 more
wiley   +1 more source

Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study

British Journal of Haematology, EarlyView.
Summary Early identification of patients at risk of failing first‐line therapy remains a key challenge in primary mediastinal B‐cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL.
L. Ceriani, L. Milan, L. Cascione, A. Di Rocco, I. Kryachok, A. J. Davies, A. Stathis, D. Rossi, P. W. M. Johnson, M. Martelli, E. Zucca   +10 more
wiley   +1 more source

Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors. [PDF]

MAbs
Danquah W, Pichery M, Eden T, Boyance A, Pasquet L, Roure V, Mars M, Marchand A, Gumz E, Gador M, Valente L, Contini M, Czernecki L, Shanmuganathan S, Barron P, Chabot S, Dangl M, Niederfellner G.   +17 more
europepmc   +1 more source

Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis

British Journal of Haematology, EarlyView.
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene, Emiliano Barbieri, Alberto Bavieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Stefano Luminari   +14 more
wiley   +1 more source

Epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: how should this regimen be positioned in current treatment algorithms? [PDF]

Transl Cancer Res
Tsuda M, Kiyasu J.
europepmc   +1 more source

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

British Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas, Mikkel Werling, Casper M. Frederiksen, Noomi Vainer, Klaus Rostgaard, Yasmin Ben‐Dali, Mariam H. Hleuhel, Christian Brieghel, Carsten U. Niemann, Caspar da Cunha‐Bang   +9 more
wiley   +1 more source

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle^TM variants. [PDF]

MAbs
Sela T, Wirth T, Sommer A, Larraillet V, Butzer J, Lohmann S, Wittmann P, Klein C, Knoetgen H, Villasenor R, Indlekofer A, Hofer K, Schumacher F, Niewöhner J.   +13 more
europepmc   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Attenuation of Oxygen-Induced Neovascularization and Inflammation by Neutralizing VEGFA and/or ANG-2 With an Antibody. [PDF]

Genes Cells
Oohashi H, Iwagawa T, Abe H, Kawaji C, Inokuchi Y, Soeda T, Saita K, Aihara M, Watanabe S.   +8 more
europepmc   +1 more source

Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma

Clinical &Experimental Allergy, EarlyView.
Forced oscillometry technique defined small airways dysfunction as a treatable trait in asthma. Monoclonal antibodies can improve small airways dysfunction, but their effects vary by mechanism of action. ABSTRACT Small airways dysfunction (SAD) is a recognised treatable trait within severe asthma, associated with worse symptom control and increased ...
Robert Greig, Philipp Suter, Rory Chan, Brian Lipworth   +3 more
wiley   +1 more source